<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03187314</url>
  </required_header>
  <id_info>
    <org_study_id>HangzhouCH08</org_study_id>
    <nct_id>NCT03187314</nct_id>
  </id_info>
  <brief_title>Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer</brief_title>
  <official_title>Phase II Study of Radiation Therapy With Anti-PD-1 Antibody SHR-1210 in Treating Patients With Unresectable Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hangzhou Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hangzhou Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy and safety of radiation therapy
      combined with anti-PD-1 antibody SHR-1210 in patients with esophageal cancer
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 14, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local control</measure>
    <time_frame>two years after enrollment</time_frame>
    <description>occurrence of local or regional progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>3 months</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by Number of participants with treatment-related adverse events as assessed by treatment-related adverse events assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>3 months</time_frame>
    <description>Objective response rate as assessed by RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Esophageal Neoplasms</condition>
  <condition>Esophageal Diseases</condition>
  <condition>Gastrointestinal Diseases</condition>
  <condition>Gastrointestinal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiation to 60 Gy, 5 x per week, for 6 weeks. Radiation begun the day after the first dose of SHR-1210. SHR-1210 (200mg fixed dose every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 60 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <description>RT to 60 Gy, 5 x per week，for 6 weeks. Radiation begun the day after the first dose of SHR-1210</description>
    <arm_group_label>Experimental Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1210</intervention_name>
    <description>SHR-1210 (200mg fixed dose every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 60 minutes.</description>
    <arm_group_label>Experimental Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age:18-75 years, male or femal.

          2. Histologically or cytologically confirmed Squamous Cell Carcinoma of the Esophagus,
             locally advanced, unresectable disease.

          3. Measurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1.

          4. Can provide either a newly obtained or archival tumor tissue sample.

          5. ECOG 0-1.

          6. Life expectancy of greater than 12 weeks.

          7. Adequate organ function.

          8. Female: child bearing potential, a negative urine or serum pregnancy test result
             within 72 h before study treatment. Participants of reproductive potential must be
             willing to use adequate contraception for the course of the study through 3 months
             after the last dose of SHR-1210.

          9. Patient has given written informed consent.

        Exclusion Criteria:

          1. Patients who have or are currently undergoing additional chemotherapy, radiation
             therapy, targeted therapy or immunotherapy.

          2. Complete obstruction of the esophagus, or patients who have the potential to develop
             perforation

          3. Other malignancy within 5 years prior to entry into the study, expect for curatively
             treated basal cell and squamous cell carcinoma of the skin and/or curatively resected
             in-situ cervical and/or breast cancers.

          4. Known central nervous system (CNS) metastases.

          5. Subjects with any active autoimmune disease or history of autoimmune disease.

          6. Uncontrolled clinically significant heart disease, including but not limited to the
             following: (1) &gt; NYHA II congestive heart failure; (2) unstable angina, (3) myocardial
             infarction within the past 1 year; (4) clinically significant supraventricular
             arrhythmia or ventricular arrhythmia requirement for treatment or intervention;

          7. Active infection or an unexplained fever &gt; 38.5°C during screening or before the first
             scheduled day of dosing (subjects with tumor fever may be enrolled at the discretion
             of the investigator);

          8. History of Interstitial Pneumonia or active non-infectious pneumonitis.

          9. Known Human Immunodeficiency Virus (HIV) infection、active Hepatitis B or Hepatitis C.

         10. Prior therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) agent.

         11. Known history of hypersensitivity to macromolecular protein preparation or any
             components of the SHR-1210 formulation.

         12. Concurrent medical condition requiring the use of cortisol (＞10mg/day Prednisone or
             equivalent dose) or other systematic immunosuppressive medications within 14 days
             before the study treament. Except: inhalation or topical corticosteroids. Doses &gt; 10
             mg/day prednisone or equivalen for replacement therapy.

         13. Has received prior anti-cancer monoclonal antibody (mAb), chemotherapy, targeted small
             molecule therapy, or radiation therapy within 4 weeks prior to study Day 1 or not
             recovered from adverse events due to a previously administered agent.

         14. Received a live vaccine within 4 weeks of the first dose of study medication.

         15. Pregnancy or breast feeding.

         16. Decision of unsuitableness by principal investigator or physician-in-charge.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hangzhou Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shixiu Wu, MD</last_name>
      <phone>+8657186826086</phone>
      <email>wushixiu@medmail.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2017</study_first_submitted>
  <study_first_submitted_qc>June 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2017</study_first_posted>
  <last_update_submitted>August 3, 2017</last_update_submitted>
  <last_update_submitted_qc>August 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hangzhou Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Shixiu Wu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Esophageal cancer</keyword>
  <keyword>Radiation</keyword>
  <keyword>Anti-PD-1 Antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Digestive System Neoplasms</mesh_term>
    <mesh_term>Esophageal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

